tiprankstipranks
Trending News
More News >
Immuron Ltd (IMRN)
NASDAQ:IMRN

Immuron (IMRN) Price & Analysis

Compare
193 Followers

IMRN Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.03%99.97%
Insiders
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors

IMRN FAQ

What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $1.50 and its highest was $2.87 in the past 12 months.
    What is Immuron Ltd’s market cap?
    Immuron Ltd’s market cap is $9.40M.
      When is Immuron Ltd’s upcoming earnings report date?
      Immuron Ltd’s upcoming earnings report date is Aug 29, 2025 which is in 72 days.
        How were Immuron Ltd’s earnings last quarter?
        Immuron Ltd released its earnings results on Feb 26, 2025. The company reported -$0.272 earnings per share for the quarter, missing the consensus estimate of -$0.013 by -$0.259.
          Is Immuron Ltd overvalued?
          According to Wall Street analysts Immuron Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Immuron Ltd pay dividends?
            Immuron Ltd does not currently pay dividends.
            What is Immuron Ltd’s EPS estimate?
            Immuron Ltd’s EPS estimate is -0.01.
              How many shares outstanding does Immuron Ltd have?
              Immuron Ltd has 5,848,975 shares outstanding.
                What happened to Immuron Ltd’s price movement after its last earnings report?
                Immuron Ltd reported an EPS of -$0.272 in its last earnings report, missing expectations of -$0.013. Following the earnings report the stock price went down -1.01%.
                  Which hedge fund is a major shareholder of Immuron Ltd?
                  Currently, no hedge funds are holding shares in IMRN

                  Company Description

                  Immuron Ltd

                  Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Relmada Therapeutics
                  Portage Biotech Inc
                  Bioxcel Therapeutics
                  Citius Pharmaceuticals
                  Hookipa Pharma
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis